Dutasteride

Dutasteride

Clinical data
Pregnancy category	US: X (Contraindicated) Not to be handled by pregnant women
Routes of administration	Oral
ATC code	G04CB02 (WHO)
Legal status
Legal status	UK: POM (Prescription only) US: ℞-only
Pharmacokinetic data
Bioavailability	60%
Protein binding	99%
Metabolism	Hepatic (CYP3A4-mediated)
Elimination half-life	5 weeks
Excretion	Fecal
Identifiers
IUPAC name (5α, 17β)-N-{2,5 bis(trifluoromethyl) phenyl}-3-oxo-4-azaandrost-1-ene-17-carboxamide
CAS Number	164656-23-9
PubChem CID	152945
DrugBank	APRD00385
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C27H30F6N2O2
Molar mass	528.53 g/mol

WikiDoc Resources for Dutasteride
Articles
Most recent articles on Dutasteride Most cited articles on Dutasteride Review articles on Dutasteride Articles on Dutasteride in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Dutasteride Images of Dutasteride Photos of Dutasteride Podcasts & MP3s on Dutasteride Videos on Dutasteride
Evidence Based Medicine
Cochrane Collaboration on Dutasteride Bandolier on Dutasteride TRIP on Dutasteride
Clinical Trials
Ongoing Trials on Dutasteride at Clinical Trials.gov Trial results on Dutasteride Clinical Trials on Dutasteride at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Dutasteride NICE Guidance on Dutasteride NHS PRODIGY Guidance FDA on Dutasteride CDC on Dutasteride
Books
Books on Dutasteride
News
Dutasteride in the news Be alerted to news on Dutasteride News trends on Dutasteride
Commentary
Blogs on Dutasteride
Definitions
Definitions of Dutasteride
Patient Resources / Community
Patient resources on Dutasteride Discussion groups on Dutasteride Patient Handouts on Dutasteride Directions to Hospitals Treating Dutasteride Risk calculators and risk factors for Dutasteride
Healthcare Provider Resources
Symptoms of Dutasteride Causes & Risk Factors for Dutasteride Diagnostic studies for Dutasteride Treatment of Dutasteride
Continuing Medical Education (CME)
CME Programs on Dutasteride
International
Dutasteride en Espanol Dutasteride en Francais
Business
Dutasteride in the Marketplace Patents on Dutasteride
Experimental / Informatics
List of terms related to Dutasteride

Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [1] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.

Overview

Dutasteride (marketed as Avodart, Avidart, Avolve, Duagen, Dutas, Dutagen, Duprost) is a 5-alpha-reductase inhibitor, a drug which inhibits the conversion of testosterone into dihydrotestosterone (DHT). It is used to treat conditions caused by DHT, such as benign prostatic hyperplasia (BPH).

Classification and Method of Action

Dutasteride belongs to a class of drugs called 5-alpha-reductase inhibitors, which block the action of the 5-alpha-reductase enzymes that convert testosterone into dihydrotestosterone (DHT). Finasteride also belongs to this group. Dutasteride inhibits both isoforms of 5-alpha reductase, while finasteride inhibits only one. But a clinical study done by GlaxoSmithKline, the EPICS trial, did not find dutasteride to be more effective than finasteride in treating BPH.

Uses

While dutasteride is officially approved to treat enlargement of the prostate gland. Clinical trials for dutasteride as a hair loss drug were undertaken, but called off in late 2002. The reason the trials were called off is not publicly known. Industry sources speculate that Avodart would have been seen as too similar to Propecia to have proved profitable as a hair loss treatment.

In December 2006, Avodart manufacturer GlaxoSmithKline embarked on a new Phase III, six month study in Korea to test the safety, tolerability and effectiveness of a once-daily dose of dutasteride (0.5mg) for the treatment of male pattern baldness in the vertex region of the scalp (types IIIv, IV and V on the Hamilton-Norwood scale). The future impact that this study will have on the FDA's approval or disapproval of Avodart for the treatment of male pattern baldness in the United States is yet to be determined.

See also

• baldness treatments
• finasteride

External links

• Effectiveness of Dutasteride as a treatment for Male Pattern Baldness, as reported by Science Daily.
• Official site
• http://www.hairlosshelp.com/html/Dutasteride_hair_loss_trials.cfm
• Information on suspended trials for Avodart as a hair loss treatment Accessed 02/09/2006